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Abstract
Background: Hepatitis C virus infection (HCV) is a communicable disease of increasing global importance with 1.75
million new infections and 400,000 related deaths annually. Until recently, treatment options have had low uptake and
most infected people remain untreated. New Direct Acting Antiviral medications can clear the virus in around 95% of
cases, with few side-effects. These medications are restricted in most countries but freely accessible in Australia, yet
most people still remain untreated. This study applies a cross-sectional research design to investigate the socio-spatial
distribution of HCV in South Australia, to identify vulnerable populations, and examine epidemiological factors to
potentially inform future targeted strategies for improved treatment uptake.
Method: HCV surveillance data were sourced from South Australia’s Communicable Diseases Control Branch and socio-
economic population data from the Australian Bureau of Statistics from January 2010 to December 2016 inclusive. HCV
cases were spatially mapped at postcode level. Multivariate logistic regression identified independent predictors of
demographic risks for HCV notification and notification source.
Results: HCV notifications (n = 3356) were seven times more likely to be from people residing in the poorest areas
with high rates of non-employment (75%; n = 1876) and injecting drug use (74%; n = 1862) reported. Notifications
among Aboriginal and Torres Strait Islander people were around six times that of non-Indigenous people. HCV
notifications negatively correlated (Spearman’s rho − 0.426; p < 0.001) with socio-economic status (residential postcode
socio-economic resources Index). History of imprisonment independently predicted HCV diagnoses in lesser
economically-resourced areas (RR1.5; p < 0.001). Independent predictors of diagnosis elsewhere than in general
practices were non-employment (RR 4.6; p = 0.028), being male (RR 2.5; p < 0.001), and younger than mean age at
diagnosis (RR 2.1; p = 0.006).
Conclusions: Most people diagnosed with HCV were from marginalised sub-populations. Given general practitioners
are pivotal to providing effective HCV treatment for many people in Australia a most concerning finding was that non-
employed people were statistically less likely to be diagnosed by general practitioners. These findings highlight a need
for further action aimed at improving healthcare access and treatment uptake to help reduce the burden of HCV for
marginalised people, and progress the vision of eliminating HCV as a major public health threat.
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Background
An estimated 80 million people live with active hepatitis
C virus infection (HCV) worldwide [1], with approxi-
mately 1.75 million new infections and 400,000 related
deaths annually [2]. In developed countries, HCV anti-
body prevalence ranges from 0.1 to 1.1% [3]. This is in
part due to the relatively high chronicity of infection
(approximately 75% of those infected [4–8]) and low
access to effective treatment [9–12]. Non-treatment typ-
ically results in the development of hepatic fibrosis
which may lead to cirrhosis and hepatocellular carcin-
oma; with related mortality occurring decades after in-
fection [4, 5, 8, 12]. Until recently, HCV treatments
globally have been expensive, poorly tolerated, and of
low curative potential such that most chronically in-
fected people remain untreated [9–12].
HCV treatments were recently transformed with Dir-
ect Acting Antiviral medications (DAAs) providing su-
perior regimens, lower toxicity, and virus clearance in
around 95% of cases [9, 11, 13–17]. Yet most countries
do not offer affordable access to DAAs due to prohibi-
tive expense [9, 18–20] and only around 7 % of people
diagnosed with HCV globally have received treatment
[2]. In response to issues with low treatment uptake, the
World Health Organization (WHO) is urging action to
ensure DAAs are affordable and accessible to people
who need them; with the aim of eliminating viral hepa-
titis as a public health threat by the year 2030 [9, 21].
In developed countries, HCV is largely transmitted
through injecting drug use (IDU) [9, 22–31]. High infec-
tion rates, poorer prognosis and burden of disease have
been associated with lower socio-economic status (SES)
[32–38]. Greater frequency of IDU and higher HCV
prevalence is associated with lower income [33, 36, 37,
39], lower education attainment [25, 33–37, 39–42], re-
duced employment [33, 34, 42–44] and homelessness
[45–53]. Conversely, higher education level and higher
paid occupation are both associated with increased
knowledge of HCV [54] and decreased HCV prevalence
[25]. Furthermore, people living with HCV commonly
perceive and report discrimination [55–60], with those
from disadvantaged and marginalised backgrounds less
likely to access treatments compared to the overall
population [38, 61, 62]. This can result in regional differ-
ences in HCV prevalence along the social gradient as
has been observed in some areas of Holland [63], France
[64], Scotland [65], United States of America [39], and
China [66]. Yet, apart from these studies, there have
been few attempts to define the burden of HCV morbid-
ity in relation to SES in most areas, including South
Australia (SA) [67].
In Australia, HCV prevalence is estimated at around 1
% [3], with approximately 230,000 HCV cases, of whom
75% are diagnosed [12, 68]. Although DAAs remain
largely inaccessible in most countries, affordable access
has been available in Australia since March 2016
through Government subsidy [9, 18, 19, 69]. Further-
more, in 2016 prescribing regulations were reformed in
Australia enabling the majority of patients with less
complicated chronic HCV infections to be treated by
general practitioners in the community. This was
followed by further reform allowing nurse practitioners
to prescribe DAAs in 2017 [70–72].
Following these advancements, HCV treatment uptake
in Australia has improved from a low of 2% for
interferon-based therapies; yet has only increased to 20%
with roll-out of the latest DAAs [12]. Thus, despite pro-
viding what is considered to be a leading model for
chronic HCV treatment [73], the majority of people in-
fected with HCV in Australia remain untreated [12, 73].
With the current treatment uptake, HCV related liver dis-
ease in Australia is projected to triple by 2030 [11].
Research revealing patterns in HCV epidemiology may
potentially better inform targeted public health interven-
tions to reach greater numbers of people living with
chronic HCV infection, improve DAA treatment uptake,
and eradicate unnecessary HCV burden [21, 74]. This study
aimed to investigate the socio-spatial distribution of newly
diagnosed HCV in South Australia and identify vulnerable
populations. Potentially, this information will guide the de-
velopment of appropriately targeted strategies with which
to improve treatment uptake among a population of people
who have affordable access to DAAs. As such, our research
may be considered an international bellwether for the
scale-up of DAAs and for the control of HCV epidemics in
developed countries.
Methods
Study design, population and setting
We conducted a cross-sectional analysis of all people
newly notified with HCV in SA from January 2010 to De-
cember 2016 inclusive. SA has a population of approxi-
mately 1.7 million, with a median age of 39.8 years. Of
these, 22% of people report being born overseas and 2%
identify as being an Indigenous Australian [75]. A great
proportion of SA’s population, around 1.3 million people,
are clustered in and around the capital city Adelaide [75].
Mandated surveillance of HCV commenced in most
Australian jurisdictions in 1997, including SA [76] where
the data for the current analysis has been sourced. SA’s
Department of Health and Ageing Communicable Dis-
ease Control Branch (CDCB) obtains HCV notifications
under State legislation [77, 78] via an advanced popula-
tion surveillance dual notification system in which la-
boratory and diagnosing medical practitioners provide
information on each episode of infection, using nation-
ally agreed case definitions for classifying HCV [79].
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De-identified HCV surveillance data were sourced
from the CDCB and Socio-economic Index for Areas
(SEIFA) data was sourced from the Australian Bureau
of Statistics (ABS) 2011 Australian Census. SEIFA is a
measure used by the ABS to rank communities in
Australia based on their socio-economic status (SES).
Higher decile scores are associated with higher SES. In
total, there were 3656 HCV cases notified to the CDCB
over the study period. SEIFA data included 1,591,731
respondents from SA [80] with a participation rate of
98.3% of the total State population. CDCB and SEIFA
data were acquired by mandate of the Commonwealth
of Australia and the SA Government under State and
Federal legislation [77, 78, 81].
The datasets
We abstracted HCV surveillance data for all SA notifica-
tions between January 2010 and December 2016 inclusive.
Cases were identified by testing positive to HCV antibody
(anti-HCV) or ribonucleic acid (RNA) amplification test
(HCV-RNA polymerase chain reaction [PCR]) for the first
time [82]. All cases were defined according to the Com-
municable Disease Network of Australia hepatitis C case
definitions [83]. Notified cases were certified as ‘Newly ac-
quired’ infections if an individual had tested positive for
HCV within 24months of a negative test; or presented
with clinical signs of acute hepatitis in conjunction with a
positive anti-HCV or RNA test [82, 83]. All other notifica-
tions were categorised as ‘Unspecified’. Ethics approval
was granted by the SA Department for Health and Ageing
Human Research Ethics Committee (Government of
South Australia).
SEIFA data were derived from the compulsory census
completed by all residents of SA on the 9th August,
2011. The SEIFA includes four indices that indicate dif-
fering collective socio-economic characteristics of
people living within postal areas. All four SEIFA indices
formed part of this analysis. The Indices differ in that
the Index of Relative Socio-Economic Disadvantage
indicates the proportion of relatively disadvantaged
people in that area; the Index of Relative Socio-Eco-
nomic Advantage and Disadvantage indicates ranks on
a continuum of most disadvantaged to most advan-
taged; the Index of Economic Resources (IER) summa-
rises variables relating to financial aspects of relative
socio-economic advantage and disadvantage; and the
Index of Education and Occupation summarises vari-
ables relating to the educational and occupational
aspects of relative socio-economic advantage and disad-
vantage [84]. The ABS broadly define socio-economic
advantage and disadvantage in relation to access to ma-
terial resources, social resources and participation in
society [84].
The census survey was self-completed by households
and represented all persons present in the residence on
that night. ABS Census Collectors were responsible for
survey delivery and collection at all dwellings; and sup-
porting homeless people to complete the survey. Collec-
tors were allocated computer-generated areas without
overlap or omission. Clear instructions for survey com-
pletion were provided by Collectors, complemented by a
national media information campaign, and efforts made
to assist people from non-English speaking backgrounds.
The survey could be completed online or in print [85].
Analysis
The statistical analysis involved three stages. Descriptive
analyses were used to check for possible errors in the
data, establish if certain variables were normally distrib-
uted, calculate measures of central tendency, and help
identify risk factors. The second stage involved bivariate
analyses, the results of which informed what variables
would be entered as independent variables in the third
stage: multivariate logistic regression modelling.
Spatial analyses were undertaken by merging HCV sur-
veillance postcode data with SEIFA using ABS 2011
Census Postal Area boundaries to enable spatial map-
ping at the postal area level (using ArcGIS version
10.4.1). In total, there were 3411 notifications for which
SA residential postcode and SEIFA rankings could be
merged. SEIFA Index deciles were then established for
every postcode, enabling the ranking of postcodes
according to SEIFA Index. We undertook correlation
analyses via Spearman’s Rho and Chi square tests to de-
termine significant relationships between HCV notifica-
tions and major demographic risks, calculating rate
ratios and rates of difference.
Collinearity was assessed using Chi-Square and Phi
statistics in relation to building five multivariate bino-
mial models. Category by category interaction for sex
and IDU in logistic regressions was initially tested and
goodness of fit was tested using the Hosmer-Lemeshow
test. In sensitivity analyses we also tested interactions
between each exposure variable of interest and sex, as
well as for IDU behaviour in the past 2 years for all
models excluding model 3, which had IDU risk behav-
iour as the outcome. Injecting drug use was more likely
in males in older age groups, however no other signifi-
cant interactions were found.
The first model aimed to establish the association be-
tween area of residence and HCV notifications using
SIEFA Indices dichotomised at the median. SEIFA IER
was used as the dependent variable to explore the social
distribution of HCV notifications (because the correl-
ation between IER HCV notifications was the strongest
relative to other indices). Explanatory variables were
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statistically significant demographic and risk factors
identified through bivariate analysis.
The second and third models aimed to identify inde-
pendent predictors among statistically significant risk
factors identified through bivariate analysis (non-employ-
ment and IDU history respectively were the dependent
variables). Explanatory variables were statistically signifi-
cant demographic and risk factors that were identified
through bivariate analysis; except where these were the
same as the dependent variable (non-employment for
Model 2 and IDU history for Model 3). With 98% (n. 300)
of people with a history of imprisonment being non-
employed, the history of imprisonment explanatory vari-
able was excluded from the second model.
Models four and five aimed to identify independent
predictors of accessing general practitioner for vulner-
able sub-populations. A binary of general practitioner
and State Government notification source was the
dependent variable with vulnerable sub populations the
explanatory variables (IDU < 2 years, employment, indi-
genous status, Australian origin and age of first IDU di-
chotomized at the median). The fourth model included
all notifications while the fifth model excluded notifica-
tions from prison health services, as these people are
incarcerated and unable to access public hospitals and
general practitioners. All models included potential
confounding variables (such as age dichotomised at the
median, sex and Australian origin). Missing data were
excluded from all statistical analyses, which were
undertaken using Stata (release 15, Stata Corporation,
College Station, TX, USA).
Results
Descriptive analysis
During the period 2010 to 2016 there were 3656 notifi-
cations, of which 91% (n = 3329) were cases of unspeci-
fied duration and 9% of infections (n = 327) were
classified as newly acquired. Annual frequencies of HCV
notifications remained relatively stable over the
seven-year period ranging from 495 in 2014 to 538 in
2013 and 2016 (Fig. 1). Age was normally distributed for
both males and females with a greater proportion of no-
tifications among males (63%). Data relating to Indigen-
ous status were missing for 2520 notifications (69%),
with 147 (13%) HCV notifications identified as Indigen-
ous Australian. Seven hundred people (22%) were re-
ported to have been born outside Australia (460 missing;
13%). Australia was the main reported country of birth
(78%, n = 2496), followed by the United Kingdom and
Ireland (2.7%, n = 86), and Vietnam (2.6%, n = 83). For
the frequencies of reported potential HCV risk factors
see Table 1.
Notifications were most frequently received from
general practitioners (primary care physicians) who
notified HCV in 55% of cases (n = 2023), with 38% (n
= 1380) from metropolitan areas (see Table 1). Notifi-
cations from major metropolitan hospitals were 18%
for males (n = 404) and 19% for females (n = 266).
Fig. 1 HCV Notifications for South Australia 2010–2016
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Notifications from Prison Health Services were
greater for males 13% (n = 295) than females 3% (n =
47). Prison Health Services notifications were highest
among Indigenous Australians, constituting 27% of
notifications. Thirty-seven percent of Indigenous
Australian male notifications (n = 29) and 16% of
Table 1 Descriptive statistics for HCV Notifications in South Australia 2010–2016
Identified Risk Factorsa Unspecified
Notifications (%)
Notifications
< 24 months (%)
Total (%)
Non-Employment 1642 (75%) 225 (90%) 1867 (77%)
Injecting Drug Use 1578 (72%) 284 (90%) 1862 (74%)
Injecting drug use in previous 24 months 1257 (57%) 275 (87%) 1532 (61%)
Birth outside Australia 683 (23%) 17 (5%) 700 (22%)
Prison history 432 (33%) 91 (45%) 523 (35%)
Tattoos 414 (35%) 69 (35%) 483 (35%)
Household Contact 149 (13%) 51 (26%) 200 (15%)
Indigenous Australian 120 (12%) 27 (28%) 147 (13%)
Healthcare related exposure 137 (11%) 1 (0.5%) 138 (10%)
Opposite-sex partner infected with HCV 94 (8%) 34 (17%) 128 (9%)
Blood Products (Outside Australia) 57 (5%) - (0%) 57 (4%)
Blood Products (Australia) 51 (4%) 1 (0.5%) 52 (4%)
Piercing (only from 2005) 49 (4%) 19 (10%) 68 (5%)
Needle Stick Injury (non HCW) 25 (2%) 13 (7%) 38 (3%)
Perinatal transmission 11 (1%) 1 (0.5%) 12 (0.9%)
Needle Stick Injury (HCW) 7 (0.6%) 2 (1%) 9 (0.7%)
Same-sex partner infected with HCV 3 (0.26%) 5 (3%) 8 (0.6%)
Notification Sources Male (%) Female (%) Total (%)
Metropolitan General Practitioner 813 (35) 567 (42) 1380 (38)
Rural or Remote General Practitioner 387 (17) 256 (19) 643 (18)
Prison Health Services 295 (13) 47 (3) 342 (9)
Royal Adelaide Hospital 176 (8) 77 (6) 253 (7)
Flinders Medical Centre 91 (4) 67 (5) 158 (4)
Drug Alcohol Services Council 95 (4) 35 (3) 130 (4)
Lyell McEwin Hospital 70 (3) 51 (4) 121 (3)
Queen Elizabeth Hospital 67 (3) 39 (3) 106 (3)
Other Public Hospitals or Health Centres 79 (3) 37 (2) 116 (3)
Other not specified 56 (2) 46 (3) 102(3)
Government Aboriginal Health Service 34 (1) 26 (2) 60 (2)
Sexually Transmitted Diseases Clinic 43 (2) 16 (1) 59 (2)
Woman’s and Children’s Hospital 4 (0) 32 (2) 36 (1)
Modbury Hospital 14 (1) 11 (1) 25 (1)
Mental Health Services 18 (1) 12 (1) 30 (1)
Australian Red Cross Blood Service 16 (1) 14 (1) 30 (1)
Aboriginal Controlled Health Services 18 (1) 9 (1) 27 (1)
Private Hospitals 14 (1) 5 (0) 19 (1)
Repatriation General Hospital 7 (0) 5 (0) 12 (0)
Cross Border Notifications 7 (0) 0 (0) 7 (0)
TOTAL 2304 (100) 2352 (99) 3656 (99)
HCV Hepatitis C virus, HCW Health Care Worker
aMultiple risk factors reported
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Indigenous Australian female notifications (n = 11)
were received from the Prison Health Service.
Descriptive statistics: spatial distribution
Of 319 SA postal areas for which SEIFA rankings and
HCV notifications could be merged, 245 residential
postcodes had HCV notifications (77%) with a median
number of three (IQR 12). Thirty-seven percent (n =
1273) of notifications resided in the lowest 10% of IER
postcodes (median 21; IQR 40) and 60 % (n = 2040) re-
sided in the lowest 20% of IER postcodes. Conversely, 1
% (n = 42) of notifications resided in the highest 10% of
IER postcodes (median 1; IQR 3). HCV notifications
therefore were seven times more likely to be from
people residing in the least economically-resourced 10%
of postcodes, and 20 times more likely compared to
people living in the wealthiest deciles.
Rural residential postcodes with greater than 50 notifi-
cations were in the areas of Murray Bridge (2.9%; n =
107), Mount Gambier (2.9%; n = 107), Port Augusta
(2.2%; n = 81) and Port Lincoln (1.7%n = 62). These com-
munities represent locations of four SA Prisons outside
the Adelaide metropolitan area. Prison Health Services
notification source, which accounted for 9% (n = 342) of
total notifications, were of greater frequency in these
areas. Notifications in Adelaide’s metropolitan postcodes
were greatest in the Adelaide Central Business District
(CBD; 4.2%; n = 155) and Enfield/Northfield (3.4%; n =
123); both areas have the largest prison populations.
Prison Services notifications in these postcodes were
38% (n = 49) and 64% (n = 74) respectively.
Greater numbers of notifications were also clustered
in the northern suburbs of the Adelaide metropolitan
area, an area that has lower socio-economic levels than
elsewhere in SA. Specifically, these were Salisbury (3.1%
n = 114), Elizabeth (3% n = 112), Davoren Park (2.6% n =
96) and Blakeview/Andrews Farm (1.7%n = 63). With
Prison Health Services notifications excluded from
spatial analysis to reflect the broader community (see
Fig. 2), the proportion of notifications clustered in these
northern suburbs increased relative to other postcodes.
A greater proportion of notifications were also recorded
in the Adelaide CBD (n = 155; 4%). In this area HCV no-
tifications had a lower mean age of 39 years (SD = 10;
t-test p-value =0.002), a greater male population (n =
134;86%; t-test p-value < 0.001) and the highest rates of
non-employment (n = 53; 87%; t-test p-value < 0.001),
IDU (n = 58; 85%; t-test p-value < 0.001) and history of
imprisonment (n = 10; 40%; t-test p-value < 0.001) for
any postcode in SA.
Bivariate analysis
All four SEIFA Indices were found to correlate nega-
tively with HCV postcode notification numbers with
the correlation stronger for the IER (Spearman’s Rho −
0.422; p < 0.001). The correlation between HCV notifi-
cations and the IER was strongest among Indigenous
Australian males (Spearman’s Rho − 0.611; p < 0.001)
followed by Indigenous Australian females (Spearman’s
Rho − 0.598; p < 0.001), total females (Spearman’s Rho
− 0.422; p < 0.001) and then males (Spearman’s Rho −
0.414; p < 0.001).
Non-employment, IDU and Prison Services contact
were significantly associated with people of Australian
origin, regardless of Indigenous status (Table 2). Birth
outside of Australia was significantly associated with
healthcare related infections and household contact.
History of imprisonment, non-employment, IDU and
being an Indigenous Australian were significantly asso-
ciated with residence in lower economically-resourced
postcodes (<= median IER score of 2; p < 0.001). Add-
itionally, needle-stick injury among healthcare workers,
having received blood products in Australia, healthcare
related exposure and tattoos were significantly associ-
ated with residence in greater economically-resourced
postcodes (> median IER score of 2; p < 0.05: see
Table 3).
Multivariate analysis
The first multivariate model (Table 4) found a history
of imprisonment, employment and female sex to inde-
pendently predict residence in the lowest two SEIFA
IER postcodes. The finding of greater employment in
the lowest two SEIFA IER postcodes (RR 1.54) is ex-
plained by the high non-employment rate of 98%
among people with a history of imprisonment dispro-
portionately represented in the lowest two SEIFA IER
postcodes (RR 1.54).
The second and third multivariate models (Model 2
and Model 3; Table 4) identified independent predic-
tors of statistically significant risk factors. The second
model found independent predictors of non-employ-
ment among people newly diagnosed with HCV were
(in rank order): injecting drugs in the previous 2
years, birth outside of Australia, being younger than
42 years of age, being an Indigenous Australian and
being female. The third model found factors inde-
pendently associated with IDU among people newly
diagnosed with HCV were: Australian origin, a history
of imprisonment, age older than 42 years and being
an Indigenous Australian. Being male also independ-
ently predicted IDU exposure but sensitivity analyses
indicated that this was only in those aged older than
42 years. Notifications from those reporting birth in
Australia were more than three and a half times more
likely to report IDU history compared to those origin-
ating from outside Australia.
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The fourth model (Model 4; Table 5) identified pre-
dictors of notification source to investigate patterns of
access to general practitioners. Prison Health Services
notifications were then removed to test notifications in
the broader community who were more able to access
general practitioners. With these removed in the final
model non-employed people, males, and people youn-
ger than 42 years of age were over 30% less likely to
attend general practitioners for HCV diagnosis (Model
5; Table 5).
Discussion
This is the first study to examine spatial distribution and
socio-economic burden of HCV at a population level in
Australia, and one of a few published studies investigat-
ing this topic worldwide. Despite the recent introduction
Fig. 2 Number of non-Prison Health Service HCV Notifications per Postal Area in South Australia’s Metropolitan area (map generated using ArcGIS
version 10.4.1)
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of affordable access to DAAs in Australia, most people
with chronic HCV infection remain untreated. Such re-
search is necessary to locate and understand areas with
higher burden of disease, more effectively target inter-
ventions and improve treatment uptake.
Inequitable distribution
In our study disproportionately high frequencies of HCV
notifications were found to cluster in particular areas; a
phenomenon consistent with research undertaken in Hol-
land [63], United States of America [39], and China [66].
Our results indicate HCV is inequitably distributed across
SA with most notifications arising in the least economically
resourced areas. HCV notifications were seven times more
likely in people residing in the poorest areas compared to
the State mean and 20 times more likely compared to the
greatest economically resourced postcodes.
This inequitable distribution of HCV notifications may
be explained, at least in part, by multiple layers of disad-
vantage occurring lower down the social gradient [86].
Sub-populations found to be vulnerable to HCV infec-
tion in this study included PWID, non-employed people,
people with history of imprisonment, and Indigenous
Australians. Our research identified these vulnerable
populations disproportionately reside in the least eco-
nomically resourced postcodes in South Australia. The
socio-spatial distribution of HCV cases in SA that we re-
vealed clearly identifies areas of greatest need for en-
hanced DAAs treatment uptake strategies.
The inner-city area of Adelaide was anomalous with a
high frequency of HCV notifications despite increased
Table 2 Bivariate analysis of HCV Notifications and Demographic Risks in South Australia 2010–2016
Rate ratio
(95%CI)
Rate difference (95%CI) p-Value*
Non-Employment
Indigenous Australian 5.04 (1.25–20.33) 0.14 (0.07–0.21) 0.007
Female 1.14 (1.00–1.29) 0.05 (0.00–0.09) 0.048
Australian origina 1.11 (1.04–1.17) 0.08 (0.03–0.12) < 0.001
IDU previous 24 months
Indigenous Australian 3.53 (2.32–5.35) 0.13 (0.10–0.17) < 0.001
Australian origin 1.58 (1.49–1.67) 0.34 (0.31–0.37) < 0.001
Male 1.45 (1.36–1.55) 0.26 (0.22–0.31) < 0.001
Injecting Drug Use
Indigenous Australian 4.93 (2.54–9.57) 0.13 (0.09–0.16) < 0.001
Australian origin 2.03 (1.87–2.22) 0.47 (0.42–0.51) < 0.001
Male 1.14 (1.06–1.22) 0.08 (0.04–0.12) < 0.001
Prison Services contact
Indigenous Australian 3.93 (2.57–6.04) 0.21 (0.14–0.28) < 0.001
Australian origin 1.52 (1.44–1.61) 0.33 (0.29–0.36) < 0.001
Male 1.45 (1.36–1.55) 0.26 (0.22–0.31) < 0.001
Tattoo
Male 1.21 (1.12–1.31) 0.13 (0.08–0.18) < 0.001
Australian origin 1.43 (1.34–1.53) 0.27 (0.22–0.31) < 0.001
Household contact
Female 1.66 (1.42–1.94) 0.21 (0.14–0.29) < 0.001
Origin outside Australia 1.22 (1.13–1.31) 0.15 (0.09–0.21) < 0.001
Healthcare related infection
Origin outside Australia 2.23 (1.86–2.66) 0.31 (0.22–0.40) < 0.001
Female 1.48 (1.23–1.78) 0.16 (0.07–0.25) < 0.001
Blood products (outside Australia)
Female 1.37 (1.04–1.83) 0.13 (− 0.00–0.26) 0.045
IDU Injecting Drug Use, HCW Health Care Worker, HCV Hepatitis C virus
*Tested using chi square
aAustralian origin includes Aboriginal and Torres Strait Islander people
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SEIFA Index scores in comparison to other cluster areas.
This may be related to the younger age, larger male popula-
tion and higher proportions of non-employment, IDU, and
history of imprisonment observed in this area. These are
risks associated with homelessness [46, 47, 87–89] which is
linked to higher rates of HCV infection in Australia,
Canada, the United Kingdom and United States of America
[45–53]. As the greatest concentration of homeless people
in SA reside in this postcode [90] further investigation into
homelessness and HCV in this area may potentially inform
targeted treatment strategies.
Injecting drug use
The proportions of cases reporting IDU as an HCV risk
factor (90% of newly acquired cases and 72% of cases of
unspecified duration) was comparable to those reported
elsewhere in Australia during the same period, and
higher than early findings in Australia of around 60–
70% during the 1990’s [74, 91, 92]. The high proportion
of PWID observed among newly diagnosed cases of
HCV has implications for healthcare access and treat-
ment uptake. People living with HCV often face stigma
and discrimination associated with IDU [55–60, 65].
This occurs in health care settings and can result in re-
duced intention by people to engage with HCV treat-
ments [55–60] or exclusion from HCV treatment by
practitioners on the basis of IDU [71, 93, 94].
IDU among HCV notified cases in this study were also
independently predicted by non-employment, a history of
imprisonment, and being an Indigenous Australian. These
findings illustrate the concept of multiple stigma, where
people experience stigma on various concurrent levels [57,
95, 96]. This has been linked to health inequities [96] and
may assist in explaining why disadvantaged and margina-
lised people living with HCV are significantly less likely to
access treatments [38, 61, 62]. Our findings support dedi-
cated HCV screening and treatment strategies intended
for PWID in SA, with focused testing shown to be
cost-effective in all settings [97–100].
Non-employment
Most notified cases of HCV were not in paid employ-
ment with higher proportions of non-employment in
Adelaide’s CBD and the northern Adelaide metropolitan
area where HCV notification frequencies were the great-
est and economic-resources most limited. This has likely
Table 3 Bivariate analysis of HCV Risks and SEIFA Economic Resources Index in South Australia 2010–2016
Rate ratio
(95%CI)
Rate difference
(95%CI)
p-Value*
HCV and SEIFA IER Post Codes
<= median score (2)
History of imprisonment 1.55 (1.44–1.66) 0.29 (0.25–0.34) < 0.001
Non-Employment 1.33 (1.21–1.46) 0.16 (0.11–0.20) < 0.001
IDU previous 24months 1.30 (1.21–1.39) 0.15 (0.11–0.19) < 0.001
Injecting Drug Use 1.20 (1.10–1.30) 0.11 (0.06–0.15) < 0.001
Indigenous Australian 1.24 (1.11–1.39) 0.15(0.07–0.23) < 0.001
Sex partner same sex HCV 1.22 (0.82–1.84) 0.14 (− 0.16–0.44) 0.419
Perinatal 1.09 (0.73–1.63) 0.06 (− 0.21–0.32) 0.692
HCV and SEIFA IER Post Codes
>median score (2)
Needle Stick Injury (HCW) 2.27 (1.73–2.97) 0.49 (−0.26–0.72) 0.005
Blood Products in Australia 1.57 (1.24–1.98) 0.22 (0.08–0.35) 0.001
Healthcare related exposure 1.36 (1.14–1.63) 0.136 (0.05–0.22) 0.002
Tattoos 1.26 (1.10–1.44) 0.09 (− 0.38–0.15) < 0.001
Needle Stick Injury (non-HCW) 1.29 (0.94–1.80) 0.114 (− 0.05–0.28) 0.154
Piercing (only from 2005) 1.22 (0.94–1.59) 0.09 (−0.38–0.21) 0.167
Blood Products (not Australian) 1.20 (0.90–1.61) 0.08 (−0.05–0.21) 0.237
Sex partner (opposite sex) has HCV 1.17 (0.95–1.44) 0.065(−0.03–0.16) 0.154
Australian origina 1.09 (0.99–1.21) 0.04 (−0.01–0.08) 0.088
Household Contact 1.05 (0.87–1.26) 0.19 (−0.06–0.09) 0.615
Bold type indicates statistical significance at p-value < 0.05
IDU Injecting Drug Use, HCW Health Care Worker, HCV Hepatitis C virus
*Tested using chi square
aAustralian origin includes Aboriginal and Torres Strait Islander people
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implications for HCV treatment uptake with unemploy-
ment both a determinant of poorer health and a barrier
to treatment [86, 101–107].
Few studies have explored healthcare access and HCV
treatment uptake among non-employed or socioeco-
nomically disadvantaged people and findings are mixed.
A French study in an area with good primary care
affordability found geographical proximity to general
practitioner, rather than socioeconomic context of
neighbourhood, was the main factor limiting hepatitis C
detection [64]. Conversely, in Scotland strong associa-
tions were found between HCV detection and socioeco-
nomic deprivation, with less convincing evidence for a
measure of travel-time to the nearest general practi-
tioner [65]. As we found a large proportion of non-
employed people newly notified with HCV were less
likely to access general practitioners in Australia, further
research to understand this is warranted.
Prison history
The high proportion of HCV cases reporting past im-
prisonment in our study is consistent with trends identi-
fied in the literature reporting high HCV prevalence in
prison settings [30, 74, 108–111], and particularly high
among Indigenous Australians and female prisoners
[109, 111–118]. Almost all notifications with history of
imprisonment in this study reported non-employment,
past IDU, and residence in lesser economically resourced
postal areas; with Indigenous Australians significantly
overrepresented. Theoretically, prison settings are there-
fore well placed to facilitate treatment access and uptake
for a large number of identified vulnerable populations.
Prison settings are also well-placed for meeting the
WHO objectives for focused testing and treatment ser-
vices [119]. In prison settings the HCV treatment cas-
cade can be supported by a single treating team using
the continuous process of awareness, testing, referral,
Table 4 Multivariate Analysis of HCV Notifications in South Australia 2010–2016
Rate ratio
(95%CI)
Rate difference
(95%CI)
p-Value*
MODEL 1:
HCV notifications in low SEIFA IER
postal areas (<= median; n = 3409)#
History of imprisonment 1.54 (1.11–2.14) 0.23 (0.00–0.45) 0.010
Employment 1.54 (1.27–1.87) 0.18 (− 0.01–0.38) < 0.001
Female 1.02 (1.01–1.02) −0.01(− 0.18–0.16) < 0.001
Non-Indigenous 1.16 (0.86–1.57) 0.15 (− 0.07–0.36) 0.322
Injecting Drugs last 2 years 1.16 (0.82–1.63) −0.12 (− 0.08–0.33) 0.397
Younger than median age (42) 1.13 (0.84–1.53) −0.05 (− 0.13–0.24) 0.421
MODEL 2:
Non-employment notifications
(n = 2425)#
Injecting drugs last 2 years 1.37 (0.18–1.59) 0.18 (0.05–0.31) < 0.001
Non-Australian origin 1.27 (1.17–0.14) 0.08 (− 0.05–0.29) < 0.001
Younger than mean age (42) 1.28 (1.07–1.41) 0.14 (− 0.03–0.24) 0.003
Indigenous Australian 1.18 (1.09–0.28) 0.13 (0.06–0.20) < 0.001
Female Sex 1.04 (1.04–1.04) 0.02 (− 0.02–0.02) < 0.001
MODEL 3:
IDU notifications (n = 3311)#
Australian origin 3.51 (1.70–7.24) 0.51 (0.37–0.66) 0.001
History of imprisonment 1.56 (1.28–1.91) 0.31 (0.18–0.44) < 0.001
Older than mean age (42) 1.12 (1.04–1.20) 0.02 (− 0.02–0.03) 0.002
Indigenous Australian 1.14 (1.06–1.23) 0.11 (0.05–0.17) < 0.001
Male Sexa 1.06 (1.06–1.06) 0.02 (0.02–0.02) < 0.001
Non-employment 1.18 (0.82–1.70) 0.15 (0.03–0.27) 0.367
Bold type indicates statistical significance at p-value < 0.05
IDU Injecting drug use
*Tested via binomial logistic regression
#Hosmer-Lemeshow test p-value > 0.05
aonly in males aged older than 42 years.
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disease stage assessment, treatment initiation and moni-
toring [9]. One example of how this process might be
established is described in the SA Government’s Prisoner
Blood Borne Virus Prevention Action Plan 2017–2020
[120]. This action plan has potential to decrease the
burden of HCV identified in vulnerable populations with
disproportionate history of imprisonment in SA.
Indigenous status
With Indigenous Australians constituting around 2% of the
SA population [75], HCV notifications for Indigenous Aus-
tralians were over six times that of non-Indigenous people.
This is higher than previously reported in Australia [82,
106, 107], and may reflect geographical differences in risk
behaviours [20]. This inequity may be explained by struc-
tural or social factors influencing position on the social gra-
dient of health [38, 86, 121]. This has been associated with
constitutional and democratic exclusion [122–125], disem-
powerment through protection and assimilation policies
[32, 126–128], and economic marginalisation [129–131];
which has reinforced racism and resulted in public health
inequities [122, 132–135]. It is widely accepted for this to
improve a focus on addressing social determinants of
health (SDH) is necessary [135–140]. This aligns with
similar findings among First Nations people in Canada
where understanding the underlying contextual socioeco-
nomic factors driving this inequity is considered essential
[141, 142].
To address health inequities that are influenced by
structural or social factors it is important for health pro-
motion strategies to extend beyond traditional
behaviour-change approaches [104, 122, 143–147]. It is
widely accepted that addressing the underpinning SDH is
crucial to correcting health inequities experienced by Indi-
genous Australians [116, 135–138, 140]. As Indigenous
populations are known to have been excluded from
healthcare services due to discrimination, or services that
are not sensitive to cultural differences, specific culturally
appropriate approaches are clearly needed to improve
HCV screening and DAAs treatment uptake among Indi-
genous Australians [2, 116, 148–153].
Access to healthcare
That non-employed people, males and younger people
with HCV are significantly less likely to be notified by
general practitioners has important implications for
HCV treatment. Most people in Australia receive pri-
mary health care through general practitioners, and
current HCV models of care are largely reliant on gen-
eral practitioners for disease stage assessment, treatment
Table 5 Multivariate Analysis of HCV Notification Source in South Australia 2010–2016
Rate ratio
(95%CI)
Rate difference
(95%CI)
p-Value*
MODEL 4
State Government (non-General Practitioner)
notification source (n = 3460) #
Non-employment 4.88 (1.27–18.86) 0.37 (− 0.21–0.53) 0.021
Male Sex 2.31 (1.50–3.57) 0.41 (0.26–0.55) < 0.001
Age at diagnosis < median (42) 1.99 (1.25–3.17) 0.36 (0.20–0.51) 0.004
Indigenous Australian 1.20 (1.04–1.38) 0.09 (− 0.01–0.19) 0.012
IDU < 2 years 1.17 (1.02–1.35) 0.08 (0.08–0.08) 0.028
Age first IDU <median (20) 1.10 (1.10–1.10) 0.07 (0.07–0.07) < 0.001
Australian origin 1.06 (0.93–1.23) − 0.05 (− 0.05–0.05) 0.38
MODEL 5
State Government (non-General Practitioner)
notification source; Non-Prison Health Service
(n = 3118)#
Non-employment 4.61 (1.18–17.94) 0.34 (0.17–0.51) 0.028
Male Sex 2.46 (1.49–4.06) 0.34 (− 0.18–0.51) < 0.001
Age diagnosed < mean (42) 2.05 (1.23–3.41) 0.31 (0.14–0.47) 0.006
Age first IDU <median (20) 1.13 (1.13–1.13) 0.05 (0.05–0.05) < 0.001
Australian origin 1.08 (0.66–1.78) − 0.06 (− 0.06—0.06) 0.75
Indigenous Australian 1.23 (0.98–1.71) 0.10 (− 0.17–0.36) 0.069
IDU < 2 years 1.29 (0.98–1.71) 0.09 (0.09–0.09) 0.07
Bold type indicates statistical significance at p-value < 0.05
IDU Injecting drug use
*Tested via binomial logistic regression
#Hosmer-Lemeshow test with p-value > 0.05
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initiation and monitoring (or in more complex cases, re-
ferral to specialist physicians) [70, 71]. Improving access
to general practitioners and supporting general practi-
tioners to initiate treatment are therefore important fac-
tors for improving DAAs treatment uptake [70, 71].
Additional approaches may also be necessary to effect-
ively target, engage, screen and provide treatment for the
vulnerable populations we’ve identified who may be experi-
encing barriers to accessing general practitioners. Among
these may include Indigenous Australians, PWID and
people from lesser economically-resourced areas. Margina-
lised people commonly perceive and report discrimination
[55–60] which can result in reduced intention to disclose
HCV status or risks and hinder engagement in treatment
[55–60]. People experiencing difficulties accessing treat-
ment via general practitioners may benefit from nurse-prac-
titioner models of care which have recently been enhanced
with authority to prescribe DAAs in some countries [154,
155], including in Australia from June 2017 [72].
Further research is recommended to design, implement
and evaluate future interventions aimed at improving
DAAs treatment uptake among the vulnerable populations
we have identified. Specifically, a qualitative methodological
approach is necessary to understand barriers to accessing
DAAs treatment, barriers to treatment initiation by general
practitioners, and alternative approaches that may be more
practical or culturally appropriate for identified vulnerable
populations. Models that have successfully improved HCV
screening and treatment uptake for marginalised people
elsewhere have involved threshold targeted Primary Health
Care Services, Mobile Medical Clinics, HCV screening in
hospital Emergency Departments, rapid diagnostic testing
and point of care testing [56, 156–160].
Limitations
Data for the current analysis were derived from a passive
surveillance system, and therefore only known cases are
included. With an estimated 25% of HCV cases undiag-
nosed in Australia (n = 57,617) [12], it is certain that cases
were missed in this study. Given these cases have not
accessed healthcare services for HCV testing it is plausible
that the results of this study relating to disadvantaged and
marginalised sub-populations are underestimated. One
ameliorating factor is that we analysed a large state-wide
database from which, consistent with our aims, we were
able to identify those sub-populations contributing most
to the notified cases in SA.
Notified cases classed as ‘newly acquired’ are established
infections of less than 24months duration. For this classifi-
cation, it is necessary for cases to present for HCV screen-
ing; and then represent for re-screening within the
24-month period. That people re-present for testing so
quickly suggests either a self-perception of greater risk of
infection or an opportunity presents for re-testing. Such
examples may include re-presenting on the occasions of
sharing injecting equipment or on re-entry to prison; with
both IDU and history of imprisonment risks particularly
high in comparison to unspecified notifications. Subse-
quently some risk factors for ‘newly acquired’ data may be
over-reported.
Although ABS Postal Areas are the closest possible ap-
proximation of State Postcodes, there may be minor dif-
ferences in ABS Postal Area and State Postcode
boundaries that could potentially create inaccurate
matching of SEIFA and CDCB data for some cases.
Conclusions
This study has mapped the areas of greatest HCV treat-
ment need in SA. Most people diagnosed with HCV were
from marginalised sub-populations and clustered in the
least economically-resourced areas. Subsequently, it is im-
perative that initiatives aiming to improve DAAs treatment
uptake target socioeconomically disadvantaged and margin-
alised sub-populations. Indigenous Australians, non-
employed people, people who have injected drugs, and
people with a history of imprisonment were at greatest risk
of HCV infection. The number of non-employed people,
young people, and males statistically less likely to be diag-
nosed with HCV by general practitioners was concerning,
with general practitioners pivotal to providing HCV treat-
ment for many people living with HCV in Australia. Al-
though further research is warranted, these findings set
forth an imperative for further action aimed at improving
DAAs treatment uptake to reduce the burden of HCV for
marginalised people, and progress the aim of eliminating
HCV as a public health threat.
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